Disease · EFO_0003759

pervasive developmental disorder - not otherwise specified

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. pervasive developmental disorder - not otherwise specified. Diseases, record EFO_0003759. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0003759

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: pervasive developmental disorder - not otherwise specified; Open Targets
Open Targets ID: EFO_0003759; Open Targets
Other names: PDD-NOS, atypical autism; Open Targets
Disease Ontology: DOID:0060042; Disease Ontology
Highest stage of its drugs: Phase 2, for 3 of its 3 drugs, from ClinicalTrials.gov; Open Targets

Drugs3

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
MEMANTINE	CHEMBL807	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ARIPIPRAZOLE	CHEMBL1112	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
MEMANTINE HYDROCHLORIDE	CHEMBL1699	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets10

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GRIN1	Glutamate [NMDA] receptor	2	Glutamate [NMDA] receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/2902	Drugs and targets
GRIN2A	Glutamate [NMDA] receptor	2	Glutamate [NMDA] receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/2903	Drugs and targets
GRIN2B	Glutamate [NMDA] receptor	2	Glutamate [NMDA] receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/2904	Drugs and targets
GRIN2C	Glutamate [NMDA] receptor	2	Glutamate [NMDA] receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/2905	Drugs and targets
GRIN2D	Glutamate [NMDA] receptor	2	Glutamate [NMDA] receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/2906	Drugs and targets
GRIN3A	Glutamate [NMDA] receptor	2	Glutamate [NMDA] receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/116443	Drugs and targets
GRIN3B	Glutamate [NMDA] receptor	2	Glutamate [NMDA] receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/116444	Drugs and targets
DRD2	D(2) dopamine receptor	1	Dopamine D2 receptor partial agonist	Phase 2	https://conductscience.org/library/genes/1813	Drugs and targets
HTR1A	5-hydroxytryptamine receptor 1A	1	Serotonin 1a (5-HT1a) receptor partial agonist	Phase 2	https://conductscience.org/library/genes/3350	Drugs and targets
HTR2A	5-hydroxytryptamine receptor 2A	1	Serotonin 2a (5-HT2a) receptor antagonist	Phase 2	https://conductscience.org/library/genes/3356	Drugs and targets

Trials4

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01592786	An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)	Phase 2	906	2014-08-07	Autism Spectrum Disorder (ASD), Autism, Autistic Disorder, Asperger's Disorder, Asperger's, Pediatric Autism, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)	MEMANTINE	Its record names the disease	ClinicalTrials.gov
NCT01592773	Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)	Phase 2	747	2015-02-16	Autism Spectrum Disorder (ASD), Autism, Autistic Disorder, Asperger's Disorder, Asperger's, Pediatric Autism, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)	MEMANTINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT01592747	Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine	Phase 2	479	2019-04-24	Autistic Disorder, Autism, Asperger's Disorder, Asperger Syndrome, Autism Spectrum Disorders, Pervasive Developmental Disorder - Not Otherwise Specified (PDD-NOS)	MEMANTINE	Its record names the disease	ClinicalTrials.gov
NCT00198055	A Study of Aripiprazole in Children and Adolescents With Aspergers and Pervasive Developmental Disorder.	Phase 2	25		Asperger's Disorder, Pervasive Developmental Disorder	ARIPIPRAZOLE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials2

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37811711	DERIVED	1	PubMed
36006807	DERIVED	2	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0003759

GET https://conductscience.org/api/diseases/v1/EFO_0003759/drugs

API reference For AI assistants